Wilfried Eberhardt

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

Julie R. Brahmer, Karen L. Reckamp, Lucio Crinò et al. · New England Journal of Medicine · 2015 · 8.6K citations · Full text

Pharmacy, Oncology, Pharmacotherapy +15

The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer

Peter Goldstraw, Kari Chansky, John Crowley et al. · Journal of Thoracic Oncology · 2016 · 4.6K citations · Full text

Medicine, Oncology, Surgery +11

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial

Robert Pirker, Jose R. Pereira, Aleksandra Szczęsna et al. · The Lancet · 2009 · 1.4K citations · Full text

Medicine, Oncology, Pharmacology +13

Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)

Leora Horn, David R. Spigel, Everett E. Vokes et al. · Journal of Clinical Oncology · 2017 · 875 citations · Full text

Medicine, Oncology, Pharmacology +16

Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer

Hossein Borghaei, Scott Gettinger, Everett E. Vokes et al. · Journal of Clinical Oncology · 2021 · 661 citations · Full text

Medicine, Oncology, Pharmacology +14